Indian Journal of Clinical and Experimental Ophthalmology
Official Publication of Innovative Education and Scientific Research Foundation
Official Publication of Innovative Education and Scientific Research Foundation
Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Case Report
Author Details :
Volume : 1, Issue : 1, Year : 2015
Article Page : 56-59
Abstract
The aim of this article is to present a clinico-pathological case report of a sweat gland tumor of eyelid that rarely undergoes malignant transformation. A 60-year-old woman presented with a painful ulcerated nodule on her eyelid which was excised with wide margins under frozen section control. The mass was sent for histopathology and after confirming tumor free margins, lid reconstruction was done by procuring a glabellar flap. Routine histopathology was diagnostic of Eccrine Acrospiroma with malignant transformation. Metastatic work up in the patient was within normal limits. The glabellar flap was healthy and no recurrence noted at one year of follow-up.
How to cite : Parija S, Panda B B, ECCRINE ACROSPIROMA OF EYELID WITH MALIGNANT TRANSFORMATION- A CASE REPORT AND REVIEW OF LITERATURE. Indian J Clin Exp Ophthalmol 2015;1(1):56-59
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
